Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2018-09-13 Major Shareholding Noti…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 2 pages 57.5KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of Ceasing to be a Substantial Holder under the Corporations Act 2001 Section 671B. It details changes in relevant interests and voting securities of a substantial holder, including dates and nature of changes. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, but a regulatory notification about shareholding changes.
2018-09-13 English
Telix completes acquisition of Atlab Pharma 3 pages 232.7KB
M&A Activity Classification · 95% confidence The document is an announcement regarding the completion of an acquisition by Telix Pharmaceuticals of Atlab Pharma. It details the terms of the acquisition, including share issuance, warrants, and intellectual property licenses. The content focuses on the transaction specifics, strategic rationale, and background information about the companies and products involved. There are no financial statements, quarterly or annual results, nor is this a transcript of a call or a regulatory filing about voting or board changes. The document is clearly an announcement of a merger/acquisition event, not a full merger proxy statement or tender offer filing. Therefore, the most appropriate classification is M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2018-09-10 English
Atlab Transaction - Market Briefing 15 pages 2.7MB
Investor Presentation Classification · 95% confidence The document is titled 'Market Briefing' and focuses on the acquisition of Atlab Pharma SAS by Telix Pharmaceuticals. It contains detailed information about the transaction terms, strategic rationale, background of the acquired companies, product pipeline, clinical data, and market opportunity. The content is presented as a detailed presentation with forward-looking statements, strategic rationale, and market analysis. There is no indication that this is a regulatory filing, audit report, earnings release, or a formal annual or interim report. The document is clearly a presentation aimed at investors or stakeholders to explain the acquisition and its strategic benefits. Therefore, the document fits best into the category of an Investor Presentation (IP). The document length (11,943 characters) and detailed content support this classification with high confidence.
2018-09-10 English
Atlab Transaction - Conference Call 2 pages 192.4KB
Regulatory Filings Classification · 95% confidence The document is an announcement of a conference call related to the completion of a transaction (Atlab Pharma SAS acquisition) by Telix Pharmaceuticals. It includes details about the call, dial-in information, and contact details for investor relations. There is no substantive financial data, detailed financial results, or report content included. The document is short (3785 characters) and serves as an invitation and information notice for an investor conference call rather than the transcript or detailed report of the call itself. Therefore, it fits best under the category of Call Transcript (CT) only if it contained the full transcript, but since it is only announcing the call, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit other categories. However, given the options, the best fit is Call Transcript (CT) if the document were the transcript, but since it is only the announcement, it is Regulatory Filings (RNS).
2018-09-10 English
Section 708A(5)(e) Notice - Cleansing Notice 1 page
Capital/Financing Update Classification · 100% confidence The document is a formal notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issue of shares and warrants by Telix Pharmaceuticals Limited without a prospectus. It details the issuance of securities, compliance with relevant provisions, and references an Appendix 3B. The content is an announcement about a capital raising event and share issuance rather than a full financial report or detailed analysis. The document length is short (1241 characters), and it serves as a regulatory announcement of a capital/financing activity. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-09-10 English
Appendix 3B - issue of consideration shares and warrants 14 pages 142.3KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, terms, issue price, purpose of the issue, and compliance with ASX rules. It references specific ASX listing rules (e.g., rule 7.1, 7.1A) and includes a quotation agreement for the securities to be listed on the ASX. The content is consistent with a formal announcement of new share issues and capital raising activities rather than a full financial report or other types of filings. The document length is substantial and contains detailed data about the capital issuance, which aligns with the definition of a Capital/Financing Update (CAP). Therefore, the appropriate classification is CAP with high confidence.
2018-09-10 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.